NBSE

NeuBase Therapeutics, Inc. Common Stock
NBSE

Overview Fund Trends Analyst Outlook Journalist POV
Delisted

NBSE was delisted on the 10th of May, 2024.

Back to rankings

34 hedge funds and large institutions have $1.94M invested in NeuBase Therapeutics, Inc. Common Stock in 2022 Q4 according to their latest regulatory filings, with 3 funds opening new positions, 5 increasing their positions, 9 reducing their positions, and 13 closing their positions.

New
Increased
Maintained
Reduced
Closed

more funds holding in top 10

Funds holding in top 10: →

less funds holding

Funds holding: →

less repeat investments, than reductions

Existing positions increased: | Existing positions reduced:

less capital invested

Capital invested by funds: $ → $

77% less first-time investments, than exits

New positions opened: 3 | Existing positions closed: 13

Holders
34
Holders Change
Holders Change %
% of All Funds
Holding in Top 10
1
Holding in Top 10 Change
Holding in Top 10 Change %
% of All Funds
New
Increased
Reduced
Closed
Calls
–
Puts
–
Net Calls
Net Calls Change

Top Buyers

1
+$7.21K
2
+$7.21K
3
+$2K
4
TRCT
Tower Research Capital (TRC)
New York
+$828
5
Wells Fargo
Wells Fargo
California
+$762

Top Sellers

1
-$345K
2
-$102K
3
-$84K
4
Goldman Sachs
Goldman Sachs
New York
-$32K
5
JAMONY
Jacob Asset Management of New York
California
-$29.9K
Name Holding Trade Value Shares
Change 		Change in
Stake
26
$2.69K
27
$2.66K
28
$2K
29
$995
30
$81
31
$48
32
$36
33
–
34
–
35
–
36
–
37
–
38
–
39
–
40
–
41
–
42
–
43
–
1
2